Comparative Pharmacology
Head-to-head clinical analysis: BLEPH 30 versus OPHTHOCHLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEPH 30 versus OPHTHOCHLOR.
BLEPH-30 vs OPHTHOCHLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BLEPH-30 is a topical formulation containing 30% sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, interfering with folic acid synthesis and exerting bacteriostatic activity against susceptible organisms.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
One drop to the affected eye(s) every 12 hours. Not to exceed 2 drops per eye per day.
Chloramphenicol 0.5% ophthalmic solution: Instill 1-2 drops into the affected eye(s) every 3-4 hours for 7-10 days. For severe infections, every 2 hours initially. Ointment: Apply a small amount (about 0.5 cm) into the conjunctival sac every 3-4 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours in adults with normal renal function; clinically, dosing intervals may need adjustment in renal impairment.
5-6 hours in normal renal function; prolonged up to 24-48 hours in severe renal impairment
Primarily renal excretion of unchanged drug, accounting for approximately 90% of elimination; minor biliary/fecal route (<10%).
Renal: 70-80% unchanged; biliary/fecal: 20-30%
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic